Two recent studies focus on the role of genetic risk scores that could provide improved identification of high-risk patients in order to improve cardiovascular outcomes. Analyses of the FOURIER and ODYSSEY OUTCOMES trials show that those patients with high genetic risk have a high cardiovascular event rate and benefit the most from treatment with a PCSK9 inhibitor.

Read more below

Read more on FOURIER genetic risk score and evolocumab benefit »

Read more on ODYSSEY predicting alirocumab benefit with genetic risk score »

The Treat Stroke to Target trial highlights the superiority of aggressive LDL-C reduction (< 70 mg/dl) over more modest reduction in patients with atherosclerotic cardiovascular disease and stroke. The trial shows that clinicians should aim to reduce LDL-C targets to <70 mg/dl in their patients with atherosclerotic stroke in order to reduce cardiovascular events.

Read the report here »

Education: the primary mission of PCSK9 Forum.

Don’t forget to check back for the latest updates to the PCSK9 Forum educational slide resource programme